Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2021,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lennox-Gastaut Syndrome (LGS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Lennox-Gastaut Syndrome (LGS): Overview
Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Children with Lennox-Gastaut syndrome may also develop cognitive dysfunction, delays in reaching developmental milestones and behavioral problems. The symptoms of Lennox-Gastaut syndrome usually begin during infancy or childhood, most often between 3 to 5 years of age. Most affected individuals experience multiple types of seizures, multiple times throughout the day. A diagnosis of Lennox-Gastaut syndrome is usually made based upon a thorough clinical evaluation, a detailed patient history and a complete physical and neurological evaluation including advanced imaging techniques, such as electroencephalography (EEG) and magnetic resonance imaging (MRI). The three main forms of treatment of Lennox-Gastaut syndrome are anti-epileptic drugs (AEDs), dietary therapy (typically the ketogenic diet) or device/surgery (VNS therapy or corpus callosotomy). Rarely, resective surgery is an option.
'Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lennox-Gastaut Syndrome (LGS) pipeline landscape is provided which includes the disease overview and Lennox-Gastaut Syndrome (LGS) treatment guidelines. The assessment part of the report embraces, in depth Lennox-Gastaut Syndrome (LGS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lennox-Gastaut Syndrome (LGS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Lennox-Gastaut Syndrome (LGS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lennox-Gastaut Syndrome (LGS) Emerging Drugs
Further product details are provided in the report……..
Lennox-Gastaut Syndrome (LGS): Therapeutic Assessment
This segment of the report provides insights about the different Lennox-Gastaut Syndrome (LGS) drugs segregated based on following parameters that define the scope of the report, such as:
Lennox-Gastaut Syndrome (LGS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lennox-Gastaut Syndrome (LGS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lennox-Gastaut Syndrome (LGS) drugs.
Lennox-Gastaut Syndrome (LGS) Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2021,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lennox-Gastaut Syndrome (LGS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Lennox-Gastaut Syndrome (LGS): Overview
Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Children with Lennox-Gastaut syndrome may also develop cognitive dysfunction, delays in reaching developmental milestones and behavioral problems. The symptoms of Lennox-Gastaut syndrome usually begin during infancy or childhood, most often between 3 to 5 years of age. Most affected individuals experience multiple types of seizures, multiple times throughout the day. A diagnosis of Lennox-Gastaut syndrome is usually made based upon a thorough clinical evaluation, a detailed patient history and a complete physical and neurological evaluation including advanced imaging techniques, such as electroencephalography (EEG) and magnetic resonance imaging (MRI). The three main forms of treatment of Lennox-Gastaut syndrome are anti-epileptic drugs (AEDs), dietary therapy (typically the ketogenic diet) or device/surgery (VNS therapy or corpus callosotomy). Rarely, resective surgery is an option.
'Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lennox-Gastaut Syndrome (LGS) pipeline landscape is provided which includes the disease overview and Lennox-Gastaut Syndrome (LGS) treatment guidelines. The assessment part of the report embraces, in depth Lennox-Gastaut Syndrome (LGS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lennox-Gastaut Syndrome (LGS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lennox-Gastaut Syndrome (LGS) R&D. The therapies under development are focused on novel approaches to treat/improve Lennox-Gastaut Syndrome (LGS).
This segment of the Lennox-Gastaut Syndrome (LGS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lennox-Gastaut Syndrome (LGS) Emerging Drugs
- Soticlestat: Takeda
Further product details are provided in the report……..
Lennox-Gastaut Syndrome (LGS): Therapeutic Assessment
This segment of the report provides insights about the different Lennox-Gastaut Syndrome (LGS) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Lennox-Gastaut Syndrome (LGS)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Lennox-Gastaut Syndrome (LGS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lennox-Gastaut Syndrome (LGS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lennox-Gastaut Syndrome (LGS) drugs.
Lennox-Gastaut Syndrome (LGS) Report Insights
- Lennox-Gastaut Syndrome (LGS) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Lennox-Gastaut Syndrome (LGS) drugs?
- How many Lennox-Gastaut Syndrome (LGS) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lennox-Gastaut Syndrome (LGS)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lennox-Gastaut Syndrome (LGS) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lennox-Gastaut Syndrome (LGS) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Takeda
- Zogenix
- Marinus Pharmaceuticals
- SK biopharmaceuticals
- CuroNZ
- TAHO Pharmaceuticals
- Axium Pharmaceuticals
- Soticlestat
- Fenfluramine
- Ganaxolone
- Carisbamate
- NRP 2945
- TAH-6601
- Lorazepam
Introduction
Executive Summary
Lennox-Gastaut Syndrome (LGS): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lennox-Gastaut Syndrome (LGS) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Soticlestat: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Ganaxolone: Marinus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NRP 2945: CuroNZ
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
TAH-6601: TAHO Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lennox-Gastaut Syndrome (LGS) Key Companies
Lennox-Gastaut Syndrome (LGS) Key Products
Lennox-Gastaut Syndrome (LGS)- Unmet Needs
Lennox-Gastaut Syndrome (LGS)- Market Drivers and Barriers
Lennox-Gastaut Syndrome (LGS)- Future Perspectives and Conclusion
Lennox-Gastaut Syndrome (LGS) Analyst Views
Appendix
Executive Summary
Lennox-Gastaut Syndrome (LGS): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lennox-Gastaut Syndrome (LGS) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Soticlestat: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Ganaxolone: Marinus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NRP 2945: CuroNZ
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
TAH-6601: TAHO Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lennox-Gastaut Syndrome (LGS) Key Companies
Lennox-Gastaut Syndrome (LGS) Key Products
Lennox-Gastaut Syndrome (LGS)- Unmet Needs
Lennox-Gastaut Syndrome (LGS)- Market Drivers and Barriers
Lennox-Gastaut Syndrome (LGS)- Future Perspectives and Conclusion
Lennox-Gastaut Syndrome (LGS) Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Lennox-Gastaut Syndrome (LGS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Lennox-Gastaut Syndrome (LGS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Lennox-Gastaut Syndrome (LGS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Lennox-Gastaut Syndrome (LGS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
